Biogen (BIIB) Cost of Revenue (2009 - 2026)

Biogen (BIIB) has reported Cost of Revenue for 18 consecutive years, with $661.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue rose 5.04% year-over-year to $661.0 million; the TTM figure through Mar 2026 stood at $2.4 billion (up 1.6% YoY), while the FY2025 annual figure was $2.4 billion, up 4.06% from the prior year.
• Cost of Revenue came in at $661.0 million for Q1 2026 at Biogen, up from $495.5 million in the prior quarter.
• The five-year high for Cost of Revenue was $674.4 million in Q3 2025, with the low at $164.0 million in Q4 2022.
• Average Cost of Revenue over 5 years is $520.4 million, with a median of $583.5 million recorded in 2024.
• Across the five-year window, Cost of Revenue sank 42.48% in 2022 and surged 255.79% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $164.0 million in 2022, then changed by 0.0% to $164.0 million in 2023, then soared by 255.79% to $583.5 million in 2024, then fell by 15.08% to $495.5 million in 2025, then soared by 33.4% to $661.0 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $661.0 million, $495.5 million, and $674.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.